Bluejay Diagnostics, INC. (BJDX) — 10-Q Filings

10-Q Filings (6)

• Bluejay Diagnostics Narrows Loss, Seeks $20M for Sepsis Test Development — Nov 7, 2025 Risk: high
  Bluejay Diagnostics, Inc. (BJDX) reported a net loss of $1,597,632 for the three months ended September 30, 2025, a decrease from the $1,481,959 net loss in the
• Bluejay Diagnostics Posts $2.5M Loss, R&D Down 20% — Aug 7, 2025 Risk: high
  Bluejay Diagnostics, Inc. reported no revenue for the quarter ended June 30, 2025, consistent with its pre-commercial stage. The company incurred a net loss of
• Bluejay Diagnostics Files Q1 2025 10-Q — May 13, 2025 Risk: low
  Bluejay Diagnostics, Inc. filed its 10-Q for the quarterly period ended March 31, 2025. The company, incorporated in Delaware with its principal executive offic
• Bluejay Diagnostics Files Q3 2024 10-Q Report — Nov 7, 2024 Risk: medium
  Bluejay Diagnostics, Inc. filed its 10-Q for the quarterly period ended September 30, 2024. The company, incorporated in Delaware, reported its financial status
• Bluejay Diagnostics Files Q2 2024 10-Q Report — Aug 14, 2024 Risk: medium
  Bluejay Diagnostics, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2024. The company, incorporated in Delaware, is based in Acton,
• Bluejay Diagnostics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: low
  Bluejay Diagnostics, Inc. (BJDX) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Bluejay Diagnostics, Inc. filed a Form 10-Q for the quarterly per

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX